Compare FSBC & PLRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | FSBC | PLRX |
|---|---|---|
| Founded | 2002 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 741.2M | 93.3M |
| IPO Year | 2021 | 2020 |
| Metric | FSBC | PLRX |
|---|---|---|
| Price | $37.78 | $1.23 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 6 | 11 |
| Target Price | ★ $37.83 | $3.79 |
| AVG Volume (30 Days) | 58.0K | ★ 1.9M |
| Earning Date | 01-26-2026 | 11-06-2025 |
| Dividend Yield | ★ 2.15% | N/A |
| EPS Growth | ★ 19.76 | N/A |
| EPS | ★ 2.70 | N/A |
| Revenue | ★ $141,930,000.00 | N/A |
| Revenue This Year | $34.35 | N/A |
| Revenue Next Year | $17.79 | N/A |
| P/E Ratio | $13.82 | ★ N/A |
| Revenue Growth | ★ 25.41 | N/A |
| 52 Week Low | $22.22 | $1.10 |
| 52 Week High | $37.74 | $15.00 |
| Indicator | FSBC | PLRX |
|---|---|---|
| Relative Strength Index (RSI) | 68.50 | 34.89 |
| Support Level | $34.49 | $1.19 |
| Resistance Level | $35.48 | $1.35 |
| Average True Range (ATR) | 0.99 | 0.12 |
| MACD | 0.32 | -0.02 |
| Stochastic Oscillator | 93.06 | 14.42 |
Five Star Bancorp is a bank holding company through its subsidiary it operates in California state-chartered non-member bank. The Company provides a broad range of banking products and services to small and medium-sized businesses, professionals, and individuals. It offers loan products like commercial real estate loans, commercial loans, commercial land and construction loans, and farmland loans and offers deposit products like checking accounts, savings accounts, money market accounts, and term certificate accounts. The group has one reportable operating segment; Banking.
Pliant Therapeutics Inc is a clinical-stage biopharmaceutical company focused on discovering and developing novel therapies for the treatment of fibrosis and related diseases. Its primary product candidate is bexotegrast (PLN-74809), an oral, small molecule, that the company is developing for the treatment of idiopathic pulmonary fibrosis, or IPF, and primary sclerosing cholangitis.